Currently, one of the most important challenges when designing a good ADC drug is to maximize its effectiveness while minimizing the non-target toxicity. In order to achieve a balance between safety and effectiveness, it is necessary to adjust and optimize each of the three structural elements of ADCs: antibody backbone, payload (cytotoxin), and a combination (linker) between them. We provide ADC services to meet clinical and commercial development needs. Our strong expertise in process development, characterization, optimization, and scale-up can support successful GMP manufacturing and productive long-term cooperative relationships with pharmaceutical companies, institutions, and universities.